Estudo randomizado | Omecamtiv Mecarbil não melhora a capacidade de exercício na insuficiência cardíaca com fração de ejeção reduzida.
16 Ago, 2022 | 12:49hEffect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)
Entrevista com os autores: Can Omecamtiv Mecarbil Improve Peak Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)? – JAMA
Comentários:
Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF – Medscape (necessário cadastro gratuito)
Conteúdo relacionado: #AHA20 – Randomized trial: In patients with systolic heart failure, Cardiac Myosin activation with Omecamtiv Mecarbil led to modest reduction in heart failure events
Comentário no Twitter
#OriginalInvestigation: Multicenter randomized clinical trial found that, in patients with chronic #HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. @GLewisCardiol https://t.co/f27Y0oya6S
— JAMA (@JAMA_current) July 20, 2022